Otsuka Holdings Co.,Ltd.: U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-month, Ready-to-Use, LAI to Treat Schizophrenia and Bipolar I Disorder in Adults

MLA

“Otsuka Holdings Co.,Ltd.: U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-to-Use, LAI to Treat Schizophrenia and Bipolar I Disorder in Adults.” Plus Company Updates, 14 Sept. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.717810914&authtype=sso&custid=ns315887.

APA

Otsuka Holdings Co.,Ltd.: U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-month, Ready-to-Use, LAI to Treat Schizophrenia and Bipolar I Disorder in Adults. (2022, September 14). Plus Company Updates.

Chicago

Plus Company Updates. 2022. “Otsuka Holdings Co.,Ltd.: U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-to-Use, LAI to Treat Schizophrenia and Bipolar I Disorder in Adults,” September 14. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.717810914&authtype=sso&custid=ns315887.